Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?

Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline? Purpose of Review To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA. Recent Findings More than 15 years ago, tumor necrosis factor inhibitors (TNFi) were the first biologic disease modifying anti- rheumatic drugs (bDMARDs) that were approved for the treatment of PsA. Since then, multiple new therapeutic agents inhibiting other targets have emerged including biologics targeting interleukin (IL) 12/23, and IL 17 and oral agents targeting phosphodi- esterase 4 (PDE4) and Janus kinases (JAKs). Many new agents with various modes of action including selective inhibition of IL 23, therapies promoting activated T cell apoptosis, inhibition of tyrosine kinase 2 (TYK2), and more are under active assessment in ongoing clinical trials. Summary Effective therapies for treating PsA have emerged over the last 15 years and newer agents continue to be discovered, allowing greater therapeutic options for controlling psoriatic disease activity and preventing joint damage and disability. Personalized therapy for patients with PsA is now a possibility. . . . . . . . . Keywords Psoriasis Spondyloarthritis TNF Th-17 Interleukin 17 Interleukin 12/23 Janus kinases Phosphodiesterase 4 Tyrosine kinase 2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Rheumatology Reports Springer Journals

Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?

Current Rheumatology Reports , Volume 20 (7) – May 30, 2018

Loading next page...
 
/lp/springer_journal/novel-therapeutics-in-psoriatic-arthritis-what-is-in-the-pipeline-DfuLnzIAwq
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Rheumatology
ISSN
1523-3774
eISSN
1534-6307
DOI
10.1007/s11926-018-0746-0
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA. Recent Findings More than 15 years ago, tumor necrosis factor inhibitors (TNFi) were the first biologic disease modifying anti- rheumatic drugs (bDMARDs) that were approved for the treatment of PsA. Since then, multiple new therapeutic agents inhibiting other targets have emerged including biologics targeting interleukin (IL) 12/23, and IL 17 and oral agents targeting phosphodi- esterase 4 (PDE4) and Janus kinases (JAKs). Many new agents with various modes of action including selective inhibition of IL 23, therapies promoting activated T cell apoptosis, inhibition of tyrosine kinase 2 (TYK2), and more are under active assessment in ongoing clinical trials. Summary Effective therapies for treating PsA have emerged over the last 15 years and newer agents continue to be discovered, allowing greater therapeutic options for controlling psoriatic disease activity and preventing joint damage and disability. Personalized therapy for patients with PsA is now a possibility. . . . . . . . . Keywords Psoriasis Spondyloarthritis TNF Th-17 Interleukin 17 Interleukin 12/23 Janus kinases Phosphodiesterase 4 Tyrosine kinase 2

Journal

Current Rheumatology ReportsSpringer Journals

Published: May 30, 2018

References